Ford Alfred J Jr
Known title: Chief Commercial OfficerCIK: 0001359446
Associated companies
Transaction History
| KMTS | ▼ Sell | Open Market | 6,275 | $151K | 8/4/2026 | View on chart |
| KMTS | ▼ Sell | Open Market | 13,015 | $311K | 8/3/2026 | View on chart |
| KMTS | ▼ Sell | Open Market | 8,681 | $196K | 7/31/2026 | View on chart |
| KMTS | ▼ Sell | Open Market | 5,936 | $135K | 7/30/2026 | View on chart |
| KMTS | ▲ Buy | Grant | 58,832 | $0 | 7/15/2026 | View on chart |
| KMTS | ▲ Buy | Grant | 25,227 | $0 | 6/3/2026 | View on chart |
| KMTS | ▲ Buy | Grant | 29,412 | $0 | 7/17/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target
BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.
Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target. BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.